Oragenics to Present at Biotech Showcase 2014
CEO Dr. John N. Bonfiglio to Present Recent Accomplishments and Development Strategy at Leading Investor Conference for Small-Cap Healthcare Companies
TAMPA, Fla.-- Oragenics, Inc. (NYSE:MKT - OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced that Dr. John N. Bonfiglio, President and Chief Executive Officer for Oragenics, is scheduled to present at Biotech Showcase™ 2014, taking place January 13-15, 2014 in San Francisco, CA. Dr. Bonfiglio will present an update on Oragenics’ company strategy and progress on Wednesday, January 15, 2014 at 3:00 p.m. PST to attending investors and pharmaceutical and healthcare executives.
Details of the presentation are as follows:
Date: Wednesday, January 15, 2014
Time: 3:00 p.m. PST
Place: Parc 55 Wyndham San Francisco, Union Square
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in more than 13 countries worldwide.
About Biotech Showcase™ 2014
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world. The 2013 edition showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. The 2013 event featured corporate presentations by 236 public and private biotechnology and life science companies, and drew 1,600 delegates who engaged in 2,500 one-to-one meetings.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.
John N. Bonfiglio, PhD, 813-286-7900 x232
Chief Executive Officer
The Ruth Group
Investor / Media Contacts
Stephanie Carrington / Aaron Estrada, 646-536-7017/7028
email@example.com / firstname.lastname@example.org
Source: Oragenics, Inc.
Released January 14, 2014